Foot, Holly;
Chan, Amy Hai Yan;
Horne, Rob;
(2024)
Development and validation of the BMQ-AIR©: a screening tool for assessing patients' treatment beliefs about switching to anti-inflammatory reliever (AIR) therapy.
Frontiers in Pharmacology
, 15
, Article 1351851. 10.3389/fphar.2024.1351851.
Preview |
PDF
fphar-15-1351851.pdf - Published Version Download (1MB) | Preview |
Abstract
Introduction: Despite anti-inflammatory reliever (AIR) therapy now being the preferred treatment choice across all severities of asthma, many patients are still “attached” to their short-acting beta2-agonist (SABA) reliever, believing this to be the best way to control their asthma. To encourage individuals to switch to AIR, it is important to first identify the beliefs that patients hold about AIR. Objective: The aim of this paper was to describe the initial development and validation of the BMQ-AIR©, a six-item screening tool which assesses and identifies patients’ treatment beliefs about switching to AIR therapy. Methods: Statements were identified from the primary literature that assessed patients’ perceptions of AIR therapy and adapted from the Beliefs about Medicines Questionnaire (BMQ). Internal reliability was examined using Cronbach’s alpha coefficient. Construct validity was evaluated by comparing scores on BMQ-AIR© with a validated measure of medication adherence and SABA beliefs. Results: A total of 446 participants completed the online survey. The BMQ-AIR© contained two subscales with three items each. Both the Necessity and Concerns subscales demonstrated good internal reliability, with Cronbach’s α-values of 0.70 and 0.69, respectively. Both subscales were negatively correlated with self-report inhaled corticosteroid adherence (Necessity: r = −0.28, p < 0.0001; Concerns: r = −0.28, p < 0.0001) and positively correlated with SRQ scores (Necessity: r = 0.51, p < 0.0001; Concerns: r = 0.44, p < 0.0001). Conclusion: Preliminary findings indicate that BMQ-AIR© demonstrates satisfactory reliability and validity. BMQ-AIR© is a promising tool that may help tailor interventions to an individual’s specific beliefs and barriers to switching to better support individuals in stopping SABA and initiating AIR therapy.
| Type: | Article |
|---|---|
| Title: | Development and validation of the BMQ-AIR©: a screening tool for assessing patients' treatment beliefs about switching to anti-inflammatory reliever (AIR) therapy |
| Location: | Switzerland |
| Open access status: | An open access version is available from UCL Discovery |
| DOI: | 10.3389/fphar.2024.1351851 |
| Publisher version: | http://dx.doi.org/10.3389/fphar.2024.1351851 |
| Language: | English |
| Additional information: | This work is licensed under a Creative Commons Attribution 4.0 International License. The images or other third-party material in this article are included in the Creative Commons license, unless indicated otherwise in the credit line; if the material is not included under the Creative Commons license, users will need to obtain permission from the license holder to reproduce the material. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/ |
| Keywords: | Science & Technology, Life Sciences & Biomedicine, Pharmacology & Pharmacy, asthma, anti-inflammatory reliever therapy, reliever, short-acting beta-2 agonists, inhaled corticosteroid, questionnaire, screening tool, BUDESONIDE-FORMOTEROL, ADHERENCE, MEDICINES, QUESTIONNAIRE, MANAGEMENT, MEDICATION, ASTHMA |
| UCL classification: | UCL UCL > Provost and Vice Provost Offices > School of Life and Medical Sciences UCL > Provost and Vice Provost Offices > School of Life and Medical Sciences > Faculty of Life Sciences UCL > Provost and Vice Provost Offices > School of Life and Medical Sciences > Faculty of Life Sciences > UCL School of Pharmacy UCL > Provost and Vice Provost Offices > School of Life and Medical Sciences > Faculty of Life Sciences > UCL School of Pharmacy > Practice and Policy |
| URI: | https://discovery-pp.ucl.ac.uk/id/eprint/10198095 |
Archive Staff Only
 |
View Item |
